Altimmune to Present at Upcoming Investor and Scientific Conferences
GAITHERSBURG, Md., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:
| 2020 BIO CEO & Investor Conference | |
| Date: | Monday, February 10 |
| Time: | 10:45am ET |
| Title: | Altimmune, Inc. Overview |
| Speaker: | Vipin K. Garg Ph. D., President and Chief Executive Officer |
| Location: | New York Marriott Marquis, New York, NY |
| Webcast: | |
| The 3rd Global NASH Conference | |
| Date: | Tuesday, February 11 |
| Time: | 11:55 am GMT / 6:55 am ET |
| Title: | Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH |
| Speaker: | M. Scott Harris M.D., Chief Medical Officer |
| Location: | The London Heathrow Marriott Hotel, London, UK |
| Presentation: | |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company’s diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield™ and NasoVAX™). For more information on Altimmune, please visit .
| Contacts | ||
| Will Brown | Ashley R. Robinson | |
| Chief Financial Officer | Managing Director LifeSci Advisors | |
| Phone: 240-654-1450 | Phone: 617-535-7742 | |
| Email: | Email: |
